Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J P Matts

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Controlled Clinical Trials|April 11, 1991
Program on the Surgical Control of the Hyperlipidemias (POSCH): patient entry characteristics. The POSCH GroupJ P Matts, H Buchwald, L L Fitch, et al.
Journal of Clinical Epidemiology|March 1, 1995
Subgroup analyses of the major clinical endpoints in the Program on the Surgical Control of the Hyperlipidemias (POSCH): overall mortality, atherosclerotic coronary heart disease (ACHD) mortality, and ACHD mortality or myocardial infarctionJ P Matts, H Buchwald, L L Fitch, et al.
JAMA|September 16, 1992
Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) GroupH Buchwald, J P Matts, L L Fitch, et al.
The New England Journal of Medicine|July 31, 1997
A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDSF M Gordin, J P Matts, C Miller, et al.
American Journal of Respiratory and Critical Care Medicine|November 1, 1996
The impact of human immunodeficiency virus infection on drug-resistant tuberculosisF M Gordin, E T Nelson, J P Matts, et al.
JAMA|March 25, 2000
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study GroupF Gordin, R E Chaisson, J P Matts, et al.
AIDS (London, England)|October 28, 1997
Susceptibility to levofloxacin of Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS Clinical Trials Group 222 Protocol TeamD C Perlman, W M El Sadr, L B Heifets, et al.
Surgery|October 1, 1982
The Program on the Surgical Control of the Hyperlipidemias: a status reportH Buchwald, R B Moore, J P Matts, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 23, 1998
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG)W M el-Sadr, D C Perlman, J P Matts, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Controlled Clinical Trials|April 11, 1991
Program on the Surgical Control of the Hyperlipidemias (POSCH): patient entry characteristics. The POSCH GroupJ P Matts, H Buchwald, L L Fitch, et al.
Journal of Clinical Epidemiology|March 1, 1995
Subgroup analyses of the major clinical endpoints in the Program on the Surgical Control of the Hyperlipidemias (POSCH): overall mortality, atherosclerotic coronary heart disease (ACHD) mortality, and ACHD mortality or myocardial infarctionJ P Matts, H Buchwald, L L Fitch, et al.
JAMA|September 16, 1992
Changes in sequential coronary arteriograms and subsequent coronary events. Surgical Control of the Hyperlipidemias (POSCH) GroupH Buchwald, J P Matts, L L Fitch, et al.
The New England Journal of Medicine|July 31, 1997
A controlled trial of isoniazid in persons with anergy and human immunodeficiency virus infection who are at high risk for tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDSF M Gordin, J P Matts, C Miller, et al.
American Journal of Respiratory and Critical Care Medicine|November 1, 1996
The impact of human immunodeficiency virus infection on drug-resistant tuberculosisF M Gordin, E T Nelson, J P Matts, et al.
JAMA|March 25, 2000
Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American Health Organization, and the Centers for Disease Control and Prevention Study GroupF Gordin, R E Chaisson, J P Matts, et al.
AIDS (London, England)|October 28, 1997
Susceptibility to levofloxacin of Myocobacterium tuberculosis isolates from patients with HIV-related tuberculosis and characterization of a strain with levofloxacin monoresistance. Community Programs for Clinical Research on AIDS 019 and the AIDS Clinical Trials Group 222 Protocol TeamD C Perlman, W M El Sadr, L B Heifets, et al.
Surgery|October 1, 1982
The Program on the Surgical Control of the Hyperlipidemias: a status reportH Buchwald, R B Moore, J P Matts, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 23, 1998
Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clinical Trials Group (ACTG)W M el-Sadr, D C Perlman, J P Matts, et al.
Pageof 5